Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Offer practical starter options for 2024, including how to evaluate coins, wallets, and purchasing steps for beginners.
23,507 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
The IMF says the U.S. economy remains robust, but mounting deficits and tariff policy threaten long-term balance. Thi...
Monster Beverage's 2025 earnings outlook centers on international growth, margin improvements, and strategic branding...
Executives say a non-technical edge—taste and judgment—could help workers survive the AI-driven jobs shakeup. Here's ...
Anthropic's Claude outage on March 2, 2026 disrupted AI workflows for thousands of developers and enterprise customer...
The Humanoid Robotics ETF BOTT surged 114% in the last year, yet its concentrated Korean and Chinese holdings expose ...
Kontoor Brands posted Q4 2025 results with revenue above $1B and a solid earnings beat, driven by a key acquisition. ...
NuScale Power stock has been under pressure as investors digest macro concerns and regulatory headwinds. This guide b...
The USDA forecasts a narrower agricultural trade deficit for FY2026, signaling policy momentum as farm markets stabil...
Water security has become the defining risk in the Iran war, shifting attention from oil to desalination infrastructu...
March 2026 brings tighter rules and sharper competition among binary options platforms. This report identifies the be...
A fresh take on a notable portfolio move: Kettle Hill Capital reveals a sizable Braze stake via a 747,715-share initi...